Advanced Oncotherapy PLC Rule 2.9 Announcement (3369Y)
May 03 2023 - 1:19PM
UK Regulatory
TIDMAVO
RNS Number : 3369Y
Advanced Oncotherapy PLC
03 May 2023
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy", "AVO" or the "Company")
Rule 2.9 Announcement - Relevant Securities in Issue
In accordance with Rule 2.9 of the Takeover Code, AVO confirms
that, as at the close of business on 2 May 2023, it had 4,975,125
senior secured fixed rate convertible loan notes ("Loan Notes") in
issue, which have a maturity date of 11 January 2024 and are
convertible into ordinary shares of 25p each in the company at a
conversion price representing a 20% discount to the next equity
fund raising undertaken by the Company. The Loan Notes pay an
interest rate of 1.25% per month and includes a revenue sharing
agreement with Harley Street Centre, as per the RNS dated 1 March
2023.
AVO also confirms that as at the close of business on 2 May 2023
its issued share capital consisted of 537,481,209 ordinary shares
of 25 pence each. The International Securities Identification
Number for the Company's ordinary shares is GB00BD6SX109.
Enquiries:
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
WH Ireland Limited (Financial adviser) Tel: +44 (0) 20 7220 1666
Antonio Bossi / James Bavister AVOPLC@whirelandcm.com
Allenby Capital Limited (Nomad and
Joint Broker)
Nick Athanas / Piers Shimwell (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Amrit Nahal / Matt Butlin (Sales & Corporate
Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RTTUOABROWUVRAR
(END) Dow Jones Newswires
May 03, 2023 13:19 ET (17:19 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Sep 2023 to Sep 2024